PET and Functional MRI, to Explore the Underlying Mechanisms of Novel Ligands Targeting Different G Protein-Coupled Receptors (GPCR) and Transporters within the CNS and the Implications of these Effects on Different Disease States, Most Notably Schizophrenia

Carrie Jones
Center for Neuroscience Drug Discovery
Director, Behavioral Pharmacology
Assistant Professor of Pharmacology
418 Preston Research Bldg.
615-322-6347 (office)
carrie.jones@vanderbilt.edu

Dr. Jones’ In Vivo Pharmacology team is dedicated to utilizing translational approaches, including assessment of changes in behavior, neurochemistry and imaging endpoints such as PET and functional MRI, to explore the underlying mechanisms of novel ligands targeting different G protein-coupled receptors (GPCR) and transporters within the CNS and the implications of these effects on different disease states, most notably schizophrenia.

For more information, please visit our lab website.